Clinical trial
Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)
Name
2019-UROMUNEINM-EU
Description
An Expanded Access Program for UROMUNE® for patients suffering from recurrent/chronic urinary tract infections of diverse etiology. This is for individuals for whom antibiotic therapy has failed, but of consideration in all cases, taking into account antibiotic-induced adverse reactions and increasing antibiotic resistance.
Trial arms
Treatment
Uromune
2 sprays of solution once daily for a total of 3 months.
Other names:
MV140
Size
-1
Eligibility criteria
Inclusion Criteria:
* Patients suffering recurrent urinary tract infections of diverse etiology.
Exclusion Criteria:
* Individuals being allergic to any of the ingredients of UROMUNE®.
* Pregnancy and breast feeding. There are neither specific studies nor a formal contraindication, the physician should value benefits/risk.
Protocol
{'studyType': 'EXPANDED_ACCESS'}
Updated at
2023-09-29
1 organization
1 product
3 indications
Organization
ImpatientsProduct
UromuneIndication
Urinary Tract InfectionsIndication
Chronic Urinary Tract InfectionIndication
Urinary Tract Infection